Santero Therapeutics key facts
as of Oct 2026- Developer of antibiotics designed to fight multiple resistant pathogens.
- Santero Therapeutics is valued at approximately $13.3M as of Oct 2026 (last reported valuation).
- It has raised $9.9M; the latest was Early Stage VC ($8.6M) in Mar 2025.
- Notable investors include SambrInvest, Société Fédérale de Participations et d'Investissement, Université Libre de Bruxelles, Newton BioCapital, Pierre Drion — 6 tracked in total.
- Status: Privately Held (backing).
Santero Therapeutics's last reported valuation, Mar 2025. Nothing priced has surfaced since.
- ·Watch Santero Therapeutics: the Monday email on marks, rounds and moves
Santero Therapeutics funding rounds
No funding rounds for Santero Therapeutics are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
Santero Therapeutics valuation
Santero Therapeutics's last reported valuation was $13.3 million in Mar 2025. No priced round, secondary trade or fund mark has surfaced since.
Santero Therapeutics investors
6 investors are on record for Santero Therapeutics, including SambrInvest, Société Fédérale de Participations et d'Investissement, Université Libre de Bruxelles and Newton BioCapital.
About Santero Therapeutics
Developer of antibiotics designed to fight multiple resistant pathogens. The company provides medicines and inhibitors for the treatment of multidrug-resistant infections with the benefit of prolonged efficacy before new resistance develops, enabling patients to get treatments with better-tolerated drugs.
- Sector
- Healthcare
- HQ
- Charleroi, Belgium
- Founded
- 2021
- Employees
- 22
- Website
- santero.be/
- Ownership
- Privately Held (backing)
Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.